Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Common Equity: 2016-2024

Historic Common Equity for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $463.2 million.

  • Rocket Pharmaceuticals' Common Equity fell 4.88% to $313.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.7 million, marking a year-over-year decrease of 4.88%. This contributed to the annual value of $463.2 million for FY2024, which is 5.96% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Common Equity stood at $463.2 million for FY2024, which was down 5.96% from $492.6 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Common Equity registered a high of $503.5 million during FY2020, and its lowest value of $454.7 million during FY2021.
  • For the 3-year period, Rocket Pharmaceuticals' Common Equity averaged around $481.8 million, with its median value being $489.7 million (2022).
  • Its Common Equity has fluctuated over the past 5 years, first soared by 63.85% in 2020, then fell by 9.69% in 2021.
  • Over the past 5 years, Rocket Pharmaceuticals' Common Equity (Yearly) stood at $503.5 million in 2020, then dropped by 9.69% to $454.7 million in 2021, then increased by 7.69% to $489.7 million in 2022, then rose by 0.59% to $492.6 million in 2023, then declined by 5.96% to $463.2 million in 2024.